MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Combining PARP inhibitors (PARPi) with CHK1 inhibitors synergistically reduced hepatocellular carcinoma (HCC) cell viability and induced DNA damage. This dual therapy shows promise for treating HCC and ovarian cancer (OC) without liver toxicity, even in resistant cases.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background
- Hepatocellular carcinoma (HCC) cells rely on Poly(ADP-ribose) polymerase 1 (PARP1) and Checkpoint kinase 1 (CHK1) for survival.
- Olaparib (PARPi) and MK-8776 (CHK1 inhibitor) are targeted therapies with potential in cancer treatment.
Purpose Of The Study
- To investigate the synergistic effects of combining olaparib and MK-8776 in HCC cells.
- To evaluate the efficacy and safety of dual PARP and CHK1 inhibition in an olaparib-resistant ovarian cancer patient-derived xenograft (PDX) model.
Main Methods
- Treatment of HepG2 HCC cells with olaparib and MK-8776.
- Assessment of cell viability, oxidative stress, DNA damage (γH2AX), and apoptosis markers (caspase-3/7).
- Evaluation of proliferation marker Ki-67 and pCHK staining in ovarian cancer PDX tumors and corresponding liver tissues.
Main Results
- Dual inhibition synergistically reduced HCC cell viability and induced oxidative stress and DNA damage.
- Combined treatment significantly increased apoptosis markers in HCC cell lines.
- Ovarian cancer PDX tumors showed reduced growth (Ki-67 decrease) without observable liver toxicity (no Ki-67 or pCHK changes in liver tissue).
Conclusions
- Dual inhibition of PARP and CHK1 is a promising therapeutic strategy for primary HCC.
- This combination therapy may be effective for ovarian cancer (OC) and olaparib-resistant tumors.
- The treatment approach appears safe regarding liver metastases and hepatotoxicity.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...